University of Texas MD Anderson Cancer Center
DelMar Pharmaceuticals' collaboration with the University of Texas, MD Anderson Cancer Center (MDACC) is focused on studying the effects of DNA damage response (DDR) pathways on the cytotoxic activity of VAL-083 against ovarian cancer subtypes and the potential for combination treatment with PARP inhibitors.
Our three-year collaboration with Duke University is to evaluate VAL-083 for activity against a range of glioblastoma subtypes (personalized drug development) and identify molecular characteristics of GBM tumors that are more likely to respond to VAL-083 than to current standard-of-care temozolomide.
University of California San Francisco
UCSF was the lead clinical site for our initial clinical trial, and a key part of increasing patient access by accelerating the overall development of this much-needed, new therapy for GBM. UCSF is also evaluating VAL-083's activity, as a single agent and as part of a combination of treatments, against pediatric high-grade glioma and medulloblastoma subtypes.
University of British Columbia
DelMar Pharmaceuticals' relationship with the University of British Columbia centers on studying DNA damage response (DDR) to VAL-083 treatment in a range of pediatric brain tumor subtypes (personalized drug treatment) and evaluating the potential for combination treatments with topoisomerase inhibitors.
Luxembourg Institute of Health
During our research with the Luxembourg Institute of Health, DelMar Pharmaceuticals was able to evaluate the potential of VAL-083, as a single agent, or as part of a combination with bevacizumab, for the treatment of hypoxic glioblastoma tumors.
B.C. Cancer Agency
DelMar Pharmaceuticals is working with the B.C. Cancer Agency to evaluate the activity of VAL-083, as a single agent or as part of combination treatments, against GBM and non-small cell lung cancer subtypes that are resistant to common chemotherapeutics.